EC 4 Good Investments For Good Friday

Good Friday is officially a holiday for the Wall Street and the U.S. stock exchanges. Except for three occasions (per Bloomberg 1898, 1906 and 1907), the New York Stock Exchange – the largest and one of the oldest exchanges of the world – has always closed on this day.

It is interesting to note that the Friday preceding Easter weekend is the only non-federal holiday on which NYSE remains closed. Although 2015 is not going to be an exception, the Labor Department’s decision to release its all-important monthly employment report will keep investors on the lookout for a better opportunity to enter the market in the next trading session.

Healthcare presents significant growth opportunity for investors. Per Factset data quoted by MarketWatch, year-to-date return for the Healthcare sector stands at 6.2% followed by consumer discretionary at 4%. It is worth noting that Healthcare was the second strongest sector in 2014 (23% return) and only lagged Utilities (24% return) by a slim margin.

Among healthcare sub-sectors, managed healthcare, biotechnology, healthcare services and medical devices are expected to perform well in the near term. We favor medical devices (equipment and instruments) companies owing to their growing importance in maintaining standard of healthcare in a cost-effective way.

The growing demand for minimally invasive technologies, in-vitro diagnostic (“IVD”) products, discrete and multiplexed assays, molecular diagnostics tools among others are key growth catalysts in our view. An aging demography is expected to boost demand for orthopedic and cardiovascular implants as well as intervertabral spacers, orthobiologics, cardiac pacemakers and many more.

Here we present 4 top-ranked stocks that sport favorable characteristics to outperform:

Inogen (INGN - Analyst Report)

This Goleta, CA-based company offers innovative respiratory products for use in the homecare setting. Inogen’s unique direct-to-customer (DTC) business model, innovative product portfolio, growing patient base, increasing international sales and expansions are expected to boost top-line growth.

Zacks Rank #1 (Strong Buy)
P/E: 72.71
Long-term EPS growth: 21%
Estimate Revision (F1): 4.8%

1 2 3
View single page >> |

By applying the Zacks Rank to mutual funds, investors can find funds that not only outpaced the market in the past but are also expected to outperform going forward. ...

more
How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.